Modified binding proteins inhibiting the vegf-a receptor interaction
AssigneeMolecular Partners AG
InventorsHans Kaspar BINZ, Patrik FORRER, Michael Tobias STUMPP
Life of this patent
Estimating the term…
Abstract
The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.
Claims8
1-15. (canceled)
A method of treating a pathological condition in a mammal including a human, comprising administering to a mammal in need thereof an effective amount of a recombinant binding protein, wherein the pathological condition is a condition which responds to the inhibition of vascular endothelial growth factor-A165 (VEGF-A165) or vascular endothelial growth factor receptor-2 (VEGFR-2), and wherein said binding protein comprises an ankyrin repeat domain and a polyethylene glycol, wherein said ankyrin repeat domain is selected from the group consisting of (1) amino acids 1 to 159 of SEQ ID NO:1, (2) amino acids 1 to 159 of SEQ ID NO:2, (3) amino acids 1 to 126 of SEQ ID NO:3, (4) amino acids 1 to 126 of SEQ ID NO:4, (5) amino acids 1 to 126 of SEQ ID NO:5, (6) amino acids 1 to 126 of SEQ ID NO:6, and (7) amino acids 1 to 159 of SEQ ID NO:7.
Dependencies are inferred from the claim text.